SpliceBio raised $135 million in a Series B round led by EQT Life Sciences and Sanofi Ventures, with support from major biotech investors. The funding will...
With the $57 million (€50 million), SpliceBio aims to bring this strategy to the clinical phase (human trials) in about 2 to 3 years. Its aim...